» Authors » Carlos G Grijalva

Carlos G Grijalva

Explore the profile of Carlos G Grijalva including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 353
Citations 11247
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bullock A, Dalton A, Stockwell M, McLaren S, Sano E, Nguyen H, et al.
Clin Infect Dis . 2025 Mar; PMID: 40036243
Background: The prevalence and risk factors for ongoing symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [SCV2]) or influenza infection are not well characterized. We conducted a prospective cohort...
2.
Antoon J, Nian H, Todd J, Ampofo K, Zhu Y, Sartori L, et al.
Hosp Pediatr . 2025 Mar; PMID: 40031991
Background: Despite national guidelines on appropriate antibiotic therapy, there is wide variation in antibiotic decision-making for children with community-acquired pneumonia. This study sought to determine prevalence and factors associated with...
3.
Griffin K, Snyder K, Javid A, Hackstadt A, Greevy R, Grijalva C, et al.
Diabetes Care . 2025 Feb; 48(3):361-370. PMID: 39977627
Objective: To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedures, between new users of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl...
4.
Quertermous B, Williams D, Bruce J, Sekmen M, Zhu Y, Grijalva C, et al.
Acad Pediatr . 2025 Feb; :102801. PMID: 39952395
Objective: The objective of this study was to determine the population-based incidence of influenza-associated serious neurologic events in children < 5 years of age. Methods: We conducted a retrospective cohort...
5.
Chan L, Morris S, Stockwell M, Bowman N, Asturias E, Rao S, et al.
Epidemics . 2025 Jan; 50:100815. PMID: 39864299
The generation time, representing the interval between infections in primary and secondary cases, is essential for understanding and predicting the transmission dynamics of seasonal influenza, including the real-time effective reproduction...
6.
Feldstein L, Ruffin J, Wiegand R, Borkowf C, James-Gist J, Babu T, et al.
J Infect Dis . 2025 Jan; PMID: 39774936
Background: Understanding protection against SARS-CoV-2 infection by vaccine and hybrid immunity is important for informing public health strategies as new variants emerge. Methods: We analyzed data from three cohort studies...
7.
King L, Andrejko K, Kobayashi M, Xing W, Cohen A, Self W, et al.
medRxiv . 2024 Dec; PMID: 39711720
Background: (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three pneumococcal conjugate vaccines (PCVs) are recommended in the United States with additional products in clinical trials....
8.
Kutty P, Jain S, Diaz M, Self W, Williams D, Zhu Y, et al.
Int J Med Sci . 2024 Dec; 21(15):3003-3009. PMID: 39628678
The burden and epidemiology of (Mp) community-acquired pneumonia (CAP) among hospitalized U. S. adults (≥ 18 years) are poorly understood. In the Etiology of Pneumonia in the Community (EPIC) study,...
9.
Lewis N, Harker E, Grant L, Zhu Y, Grijalva C, Chappell J, et al.
Clin Infect Dis . 2024 Nov; PMID: 39607747
Background: clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods: A multicenter US observational sentinel surveillance network prospectively enrolled...
10.
Biddle J, Nguyen H, Talbot H, Rolfes M, Biggerstaff M, Johnson S, et al.
J Infect Dis . 2024 Nov; PMID: 39602819
Asymptomatic influenza virus infection occurs but may vary by factors such as age, vaccination status, or season. We examined the frequency of influenza virus infection and symptoms using data from...